Fellows National Lipid Association Self-Assessment Program (NLA-SAP)

Title:

Fellows National Lipid Association Self-Assessment Program (NLA-SAP)

Topic: Cardiology
Relevant Terms: Lipidology
Primary Audience: Fellows in Training
Launch Date: 01-Sep-13
Expiration Date: The accreditation for this activity has expired.
PROGRAM OVERVIEW
The Fellows National Lipid Association Self-Assessment Program (NLA-SAP) was developed to provide fellows-in-training the opportunity to assess their core knowledge of lipidology.
 
OBJECTIVES
  1. Explain lipoprotein metabolism and its role in the pathogenesis of atherosclerosis.
  2. Identify the genetic causes of low and high serum HDL-C and LDL-C and the pathophysiologic implications of these disorders.
  3. Discuss the genetic causes of low and high serum triglycerides and the pathophysiologic implications of these disorders.
  4. Identify special patient populations at high cardiometabolic risk.
  5. Identify traditional and emerging risk factors for the development of atherosclerotic vascular disease.
  6. Outline the complexities of cardiometabolic risk management in patients who are overweight or obese.
  7. Evaluate the use of biomarkers in the prevention and treatment of atherosclerosis.
  8. Utilize effective treatment strategies for the management of multiple cardiometabolic risk factors.
  9. Describe the pathophysiology of type-2 diabetes and metabolic syndrome, including the characteristics of atherogenic dyslipidemia found in these patients.
  10. Review the role of subclinical atherosclerosis testing in cardiovascular disease risk assessment and management.
  11. Review the role of blood biomarkers in cardiovascular disease risk assessment and management.
  12. Outline current issues and approaches to global risk assessment.
  13. Review the role of coronary CT angiography in cardiovascular disease risk assessment and management.
  14. Describe effective diet and lifestyle strategies for long-term obesity and dyslipidemia management.
  15. Review the mechanism of action of plant sterols/stanols and the role of these functional foods in the management of hypercholesterolemia.
  16. Review the role of various types to physical activity on dyslipidemia and cardiovascular risk.
  17. Review the mechanism of action of soluble dietary fiber on lipids and cardiovascular health.
  18. Outline the basic principles of exercise prescription for the management of dyslipidemia and overweight/obesity.
  19. Identify the impact of various types of dietary fats and carbohydrates on lipids and coronary heart disease risk.
  20. Identify the impact of omega-3 fatty acids on lipids and coronary heart disease risk.
  21. Review the mechanism of action, pharmacokinetics, and efficacy of available FDA approved drugs for the management of lipid disorders.
  22. Discuss the impact of lipid medication on lipoprotein metabolism.
  23. Assess the status of new and emerging treatment options for cholesterol and triglyceride management.
  24. Describe the appropriate use of lipid-altering drugs in special populations.
  25. Review clinical trials of lipid-altering drug therapies used in cardiovascular disease prevention.
  26. Assess the side effects of lipid-altering drugs to encourage their safe use in cardiovascular disease prevention.
  27. Describe appropriate use of subclinical atherosclerosis testing and serum biomarkers in selected patient populations.
  28. Identify evidence-based lifestyle change and pharmacologic therapy for specific populations of patients with dyslipidemia.
  29. Assess the impact of HIV disease and treatment on lipid metabolism.
  30. Review appropriate management of dyslipidemia in patients with HIV/AIDS.
  31. Describe the impact of medications used in organ transplantation patients on lipid metabolism.
  32. Review the mechanisms of dyslipidemia in secondary dyslipidemias.
     
Program Faculty
 
EDITOR-IN-CHIEF
Carl E. Orringer, MD, FACC, FNLA*
Harrington Chair in Preventive Cardiovascular Medicine
University Hospitals Case Medical Center
Harrington Heart and Vascular Institute
Associate Professor of Medicine
Case Western Reserve University School of Medicine
Cleveland, OH
 
ASSOCIATE EDITORS
Vera Bittner, MD, MSPH, FNLA*
Professor of Medicine
Section Head, Preventive Cardiology
University of Alabama
Birmingham, AL
 
Eliot A. Brinton, MD, FAHA, FNLA*
Director, Atherometabolic Research
Utah Foundation for Biomedical Research
Salt Lake City, UT
 
Terry Jacobson, MD, FACP, FAHA, FNLA*
Professor of Medicine
Director, Office of Health Promotion and
Disease Prevention
Emory University School of Medicine
Atlanta, GA
 
James A. Underberg, MS, MD, FACPM, FACP, FASH, FNLA*
Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
New York, NY
 
CONTRIBUTING EDITORS
The NLA wishes to acknowledge below the faculty who provided content for the NLA-SAP.
 
Harold E. Bays, MD, FTOS, FACE, FNLA*
Medical Director/President
Louisville Metabolic and Atherosclerosis Research Center
Louisville, KY
 
Eliot A. Brinton, MD, FAHA, FNLA*
Director, Atherometabolic Research
Utah Foundation for Biomedical Research
Salt Lake City, UT
 
Alan S. Brown, MD FACC, FNLA*
Medical Director
Midwest Heart Disease Prevention Center
Interventional Cardiologist
Midwest Heart Specialists – Advocate Medical Group
Clinical Associate Professor of Medicine
Loyola University Strich School of Medicine
Chicago, IL
 
Thomas D. Dayspring, MD, FACP, FNLA, NCMP*
Director of Cardiovascular Education
Foundation for Health Improvement and Technology
Richmond, VA
 
Penny M. Kris-Etherton, PhD, RD, CLS, FNLA†
Distinguished Professor of Nutrition
Department of Nutritional Sciences
Penn State University
University Park, PA
 
Samuel Gidding, MD
Cardiology Division Head
Nemours Cardiac Center
A.I. DuPont Hospital for Children
Professor of Pediatrics
Thomas Jefferson University
Wilmington, DE
 
Ralph L. La Forge, MSc, CLS, FNLA†
U.S. Indian Health Service
Diabetes Treatment and Prevention Division
Consulting Faculty
Duke University Endocrine, Metabolism, and Nutrition
Division
Durham, NC
 
Edgar V. Lerma, MD, FNLA
Clinical Professor of Medicine
Section of Nephrology
University of Illinois at Chicago College of Medicine
Educational Coordinator for Nephrology
UIC- Advocate Christ Medical School
Oak Lawn, IL
 
Kevin Maki, PhD, CLS, FNLA†
Chief Science Officer Biofortis
Clinical Research
Addison, IL
 
Carl E. Orringer, MD, FACC, FNLA*
Harrington Chair in Preventive Cardiovascular Medicine
University Hospitals Case Medical Center
Harrington Heart and Vascular Institute
Associate Professor of Medicine
Case Western Reserve University School of Medicine
Cleveland, OH
 
Vasudevan A. Raghavan, MBBS, MD, MRCP (UK)*
Associate Professor of Internal Medicine
Texas A&M Health Sciences Center
Director, Cardiometabolic, Lipid Clinic and Medical
Weight Management Services
Division of Endocrinology
Scott and White Center for Diagnostic Medicine
Temple, TX
 
Joseph J. Saseen, PharmD, FASHP, FCCP, BCPS, CLS, FNLA†
Professor and Vice Chair
Department  of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
Professor
Department  of Family Medicine
University of Colorado
Aurora, CO
 
James A. Underberg, MS, MD, FACPM, FACP, FASH, FNLA*
Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
New York, NY
 
Robert A. Wild, MD, PhD, MPH, FNLA*
Professor and Chief Gynecology
VA Medical Center
Professor Ob/Gyn, Medicine, Family and Preventive Medicine
Professor Clinical Epidemiology and Biostatistics
Oklahoma City, OK
 
*Denotes Diplomate, American Board of Clinical Lipidology.
†Denotes Diplomate, Accreditation Council for Clinical Lipidology.
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 18.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux
Safari 4.0+ for Mac OSX 10.5 and above